Drug resistance in B-cell chronic lymphocytic leukemia

Predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay

Yanping Zhong, Antony C. Bakke, Guang Fan, Rita Braziel, Ken Gatter, Jose F. Leis, Richard Maziarz, James Z. Huang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Patients with B-cell chronic lymphocytic leukemia (B-CLL) often demonstrate variable responses to similar treatments. It would be highly desirable to develop a personalized therapeutic strategy for selection of appropriate drugs or regimens based on the drug sensitivity profiles of leukemic cells from individuals. Methods: We applied a multiparameter flow cytometric drug cytotoxicity assay to evaluate drug effects specifically on B-CLL cells from 43 individuals after leukemic cells were incubated in vitro with fludarabine, chlorambucil, cladribine, or prednisolone. Results: We demonstrated that different B-CLL cell populations from 43 individuals showed a marked variability in drug sensitivity. In vitro resistance to fludarabine was greatest in B-CLL cells with deletions of p53, a cytogenetic abnormality that is almost invariably associated with a poor therapeutic response clinically. Conclusions: In vitro drug sensitivity profiles analyzed by a multiparameter flow cytometric cytotoxicity assay may serve as a tool to facilitate individualized selection of appropriate drugs for treatment in B-CLL. Prospective trials will be needed to validate the clinical utility of this flow cytometric cytotoxicity assay.

Original languageEnglish (US)
Pages (from-to)189-195
Number of pages7
JournalCytometry Part B - Clinical Cytometry
Volume72
Issue number3
DOIs
StatePublished - May 15 2007

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Drug Resistance
Pharmaceutical Preparations
Cladribine
Chlorambucil
Therapeutics
Prednisolone
In Vitro Techniques
Chromosome Aberrations
Population

Keywords

  • Chronic lymphocytic leukemia
  • Cytotoxicity assay
  • Drug sensitivity
  • Flow cytometry

ASJC Scopus subject areas

  • Hematology
  • Cell Biology
  • Pathology and Forensic Medicine
  • Biophysics
  • Endocrinology

Cite this

Drug resistance in B-cell chronic lymphocytic leukemia : Predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay. / Zhong, Yanping; Bakke, Antony C.; Fan, Guang; Braziel, Rita; Gatter, Ken; Leis, Jose F.; Maziarz, Richard; Huang, James Z.

In: Cytometry Part B - Clinical Cytometry, Vol. 72, No. 3, 15.05.2007, p. 189-195.

Research output: Contribution to journalArticle

@article{8f61e01c4062460480f5c99694a2faa6,
title = "Drug resistance in B-cell chronic lymphocytic leukemia: Predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay",
abstract = "Background: Patients with B-cell chronic lymphocytic leukemia (B-CLL) often demonstrate variable responses to similar treatments. It would be highly desirable to develop a personalized therapeutic strategy for selection of appropriate drugs or regimens based on the drug sensitivity profiles of leukemic cells from individuals. Methods: We applied a multiparameter flow cytometric drug cytotoxicity assay to evaluate drug effects specifically on B-CLL cells from 43 individuals after leukemic cells were incubated in vitro with fludarabine, chlorambucil, cladribine, or prednisolone. Results: We demonstrated that different B-CLL cell populations from 43 individuals showed a marked variability in drug sensitivity. In vitro resistance to fludarabine was greatest in B-CLL cells with deletions of p53, a cytogenetic abnormality that is almost invariably associated with a poor therapeutic response clinically. Conclusions: In vitro drug sensitivity profiles analyzed by a multiparameter flow cytometric cytotoxicity assay may serve as a tool to facilitate individualized selection of appropriate drugs for treatment in B-CLL. Prospective trials will be needed to validate the clinical utility of this flow cytometric cytotoxicity assay.",
keywords = "Chronic lymphocytic leukemia, Cytotoxicity assay, Drug sensitivity, Flow cytometry",
author = "Yanping Zhong and Bakke, {Antony C.} and Guang Fan and Rita Braziel and Ken Gatter and Leis, {Jose F.} and Richard Maziarz and Huang, {James Z.}",
year = "2007",
month = "5",
day = "15",
doi = "10.1002/cyto.b.20117",
language = "English (US)",
volume = "72",
pages = "189--195",
journal = "Cytometry Part B - Clinical Cytometry",
issn = "1552-4949",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Drug resistance in B-cell chronic lymphocytic leukemia

T2 - Predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay

AU - Zhong, Yanping

AU - Bakke, Antony C.

AU - Fan, Guang

AU - Braziel, Rita

AU - Gatter, Ken

AU - Leis, Jose F.

AU - Maziarz, Richard

AU - Huang, James Z.

PY - 2007/5/15

Y1 - 2007/5/15

N2 - Background: Patients with B-cell chronic lymphocytic leukemia (B-CLL) often demonstrate variable responses to similar treatments. It would be highly desirable to develop a personalized therapeutic strategy for selection of appropriate drugs or regimens based on the drug sensitivity profiles of leukemic cells from individuals. Methods: We applied a multiparameter flow cytometric drug cytotoxicity assay to evaluate drug effects specifically on B-CLL cells from 43 individuals after leukemic cells were incubated in vitro with fludarabine, chlorambucil, cladribine, or prednisolone. Results: We demonstrated that different B-CLL cell populations from 43 individuals showed a marked variability in drug sensitivity. In vitro resistance to fludarabine was greatest in B-CLL cells with deletions of p53, a cytogenetic abnormality that is almost invariably associated with a poor therapeutic response clinically. Conclusions: In vitro drug sensitivity profiles analyzed by a multiparameter flow cytometric cytotoxicity assay may serve as a tool to facilitate individualized selection of appropriate drugs for treatment in B-CLL. Prospective trials will be needed to validate the clinical utility of this flow cytometric cytotoxicity assay.

AB - Background: Patients with B-cell chronic lymphocytic leukemia (B-CLL) often demonstrate variable responses to similar treatments. It would be highly desirable to develop a personalized therapeutic strategy for selection of appropriate drugs or regimens based on the drug sensitivity profiles of leukemic cells from individuals. Methods: We applied a multiparameter flow cytometric drug cytotoxicity assay to evaluate drug effects specifically on B-CLL cells from 43 individuals after leukemic cells were incubated in vitro with fludarabine, chlorambucil, cladribine, or prednisolone. Results: We demonstrated that different B-CLL cell populations from 43 individuals showed a marked variability in drug sensitivity. In vitro resistance to fludarabine was greatest in B-CLL cells with deletions of p53, a cytogenetic abnormality that is almost invariably associated with a poor therapeutic response clinically. Conclusions: In vitro drug sensitivity profiles analyzed by a multiparameter flow cytometric cytotoxicity assay may serve as a tool to facilitate individualized selection of appropriate drugs for treatment in B-CLL. Prospective trials will be needed to validate the clinical utility of this flow cytometric cytotoxicity assay.

KW - Chronic lymphocytic leukemia

KW - Cytotoxicity assay

KW - Drug sensitivity

KW - Flow cytometry

UR - http://www.scopus.com/inward/record.url?scp=34247581207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247581207&partnerID=8YFLogxK

U2 - 10.1002/cyto.b.20117

DO - 10.1002/cyto.b.20117

M3 - Article

VL - 72

SP - 189

EP - 195

JO - Cytometry Part B - Clinical Cytometry

JF - Cytometry Part B - Clinical Cytometry

SN - 1552-4949

IS - 3

ER -